HEADSTART-ACS study conducted in collaboration with Indonesia’s National Cardiovascular Center in world’s fourth most ...

TG Therapeutics, Inc. (NASDAQ: TGTX), today announced several updated poster presentations at MSToronto2026, the 10th Joint ...

Cosentyx® (secukinumab) becomes first and only IL-17A inhibitor approved in Europe for adults with PMR, 1 a common ...

Randomized, Double-Blind Phase 2b Data in 327 Patients, Plus New Mechanistic Research, to Be Presented October 23 in Denver ...

Prospective, multicenter FDA IDE study found an IRE-based treatment strategy was associated with longer overall survival in ...

(NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today ...

Schrödinger is transforming molecular discovery with its computational platform, which enables the discovery of novel, highly ...

(NYSE: COR) today announced it has signed a definitive agreement to acquire American Oncology Network, Inc. (“AON”) (OTCQX: ...

Hibsago’s approval—a functional cure for certain patients with a hepatitis B infection—further validates Ionis ...

United Therapeutics Corporation (Nasdaq: UTHR) announced today that it will report its third quarter 2026 financial results ...

Company to host conference call and webcast on November 5, 2026, at 8:00 a.m. ET (9:00 p.m. HKT) SHANGHAI & CAMBRIDGE, Mass.- ...

Arbor Biotechnologies, Inc., a biotechnology company discovering and developing the next generation of genetic medicines, ...